Pfizer Share Price Today | Stock Price & Pfizer Share Screener
As of November 19, 2026, the live Pfizer share price (NSE: PFIZER) is ₹3,850.30 on NSE and ₹3,849.70 on BSE, up 0.22% from the previous close, with shares trading between ₹3,801.20 and ₹3,859.90 in today's trading session, and a 52-week range of ₹3,612.30–₹5,197.80. Track PFIZER market value to gauge the company's total market size. Use the Pfizer stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Pfizer opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹2,967 and net income of ₹859, with EBITDA of ₹1,227, an operating margin of 34.0% and a profit margin of 29.0%.
Pfizer Share Price Chart
Track the current stock price of Pfizer with an interactive chart. Analyse PFIZER share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Pfizer stock quote in one place.
The quote of ₹3,850.30 sits between the 52-week low of ₹3,612.30 and the 52-week high of ₹5,197.80, and the latest session moved 0.22% from the previous close.
Pfizer Company Profile - Fundamental Screener
Screen Pfizer company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PFIZER shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Pradip Shah listed as chairperson or CEO, and it trades under ISIN INE182A01018.
Business Overview
Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives,...more
Company Details
Classification
Identifiers and Leadership
Pfizer Balance Sheet Screener
Screen PFIZER balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹4,922, up from ₹4,911 in 2025.
Latest statistics put total assets at ₹4,922 and shareholder funds at ₹4,203, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 4,922 | 4,911 | 4,229 | 4,001 | 3,901 | 3,266 | 4,405 | 3,940 | 3,690 | 3,261 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 678 | 724 | 713 | 749 | 869 | 894 | 973 | 886 | 950 | 902 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 92 | 124 | 87 | 136 | 183 | 99 | 137 | 37 | 52 | 62 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4,203 | 4,217 | 3,596 | 3,207 | 2,864 | 2,393 | 3,396 | 3,011 | 2,683 | 2,419 |
| Share Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves & Surplus | 4,157 | 4,172 | 3,550 | 3,162 | 2,819 | 2,347 | 3,350 | 2,966 | 2,637 | 2,373 |
Pfizer Income Statement Screener - Profit & Revenue Analysis
Screen Pfizer income statement and profit fundamentals. Analyze PFIZER quarterly results. Pfizer reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹2,967 and net profit was ₹859, equal to earnings per unit of ₹187.80, at an operating margin of 34%.
In that period expenses were ₹1,740, interest cost ₹9 and tax ₹303. The next period listed, 2026-March, shows revenue of ₹2,708 and net profit of ₹722.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 2,967 | 2,708 | 2,454 | 2,374 | 2,526 | 2,674 | 2,320 | 2,336 | 2,249 | 2,083 | 2,067 | 2,103 | 1,921 |
| Expenses | 1,740 | 1,616 | 1,541 | 1,558 | 1,616 | 1,775 | 1,526 | 1,579 | 1,516 | 1,468 | 1,617 | 1,586 | 1,470 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 1,227 | 1,092 | 913 | 816 | 910 | 898 | 793 | 757 | 733 | 615 | 450 | 517 | 450 |
| Operating Profit % | 34.00% | 36.00% | 32.00% | 29.00% | 33.00% | 32.00% | 32.00% | 27.00% | 27.00% | 25.00% | 18.00% | 21.00% | 21.00% |
| Depreciation | 58 | 58 | 61 | 62 | 106 | 115 | 109 | 103 | 71 | 66 | 63 | 124 | 131 |
| Interest | 9 | 10 | 8 | 15 | 13 | 11 | 15 | 11 | 1 | 0 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 1,160 | 976 | 1,016 | 746 | 824 | 773 | 669 | 643 | 660 | 548 | 517 | 402 | 238 |
| Tax | 303 | 253 | 249 | 195 | 200 | 160 | 171 | 133 | 231 | 188 | 180 | 179 | 138 |
| Net Profit | 859 | 722 | 768 | 551 | 624 | 613 | 498 | 509 | 429 | 360 | 337 | 223 | 100 |
| EPS | 187.80 | 157.92 | 167.79 | 119.22 | 136.38 | 133.89 | 108.77 | 111.28 | 93.78 | 78.70 | 73.61 | 66.66 | 15.26 |
Pfizer Cash Flow Screener - Liquidity Fundamentals
Screen PFIZER cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹968, and net cash flow was an outflow of ₹392.
Over the same period, investing activities used ₹562 and financing activities used ₹798.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 968 | 660 | 257 | 356 | 667 | 427 | 323 | 98 | 332 | 329 |
| Investing Activities | -562 | -71 | 54 | -36 | -575 | -469 | 1,530 | 35 | -238 | -250 |
Financing and Net Cash | ||||||||||
| Financing Activities | -798 | -205 | -235 | -346 | -181 | -1,571 | -164 | -110 | -110 | -83 |
| Net Cash Flow | -392 | 383 | 75 | -26 | -88 | -1,613 | 1,690 | 23 | -17 | -4 |
Pfizer Shareholding Pattern Screener
See Pfizer shareholding pattern with promoter, FII, and DII holdings. Check Pfizer promoter holding and ownership changes for PFIZER on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 63.92%, foreign institutions 2.81%, domestic institutions 16.89% and the public 11.87%, spread across 99,545 shareholders.
The shareholder count was 99,545 in 2026-Mar, compared with 102,478 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
Institutional Investors | ||||||||
| FII Holding | 2.81% | 1.65% | 1.63% | 2.18% | 2.39% | 2.60% | 2.71% | 3.33% |
| DII Holding | 16.89% | 17.80% | 17.52% | 17.10% | 17.23% | 17.10% | 17.05% | 15.33% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 11.87% | 12.04% | 12.20% | 12.34% | 12.02% | 12.08% | 11.93% | 12.90% |
| Other Holding | 4.51% | 4.59% | 4.72% | 4.45% | 4.43% | 4.29% | 4.39% | 4.52% |
| Shareholder Count | 99,545 | 102,478 | 104,472 | 108,261 | 103,222 | 103,480 | 100,933 | 109,214 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Pfizer. Pfizer dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹75.00 per unit for 2026-March, a yield of 1.97%, compared with ₹165.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹75.00, ₹165.00 and ₹35.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹75.00 | 1.97% |
| 2025-March | ₹165.00 | 3.50% |
| 2024-March | ₹35.00 | 0.87% |
| 2023-March | ₹40.00 | 0.95% |
| 2022-March | ₹35.00 | 1.00% |
| 2021-March | ₹35.00 | 0.80% |
| 2020-March | ₹330.00 | 7.29% |
| 2019-March | ₹22.50 | 0.56% |
| 2018-March | ₹20.00 | 0.60% |
| 2017-March | ₹20.00 | 0.92% |
Pfizer Stock Index Membership - Nifty & Sensex
See which indices include Pfizer stock. Check PFIZER index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 14 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Pfizer Market Events Screener - Corporate Actions
Get Pfizer corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Pfizer stock events that may affect PFIZER share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.
It is followed by Quarterly Result Announcement dated July 28, 2026 and Annual General Meeting dated July 28, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-03 | 2026-11-03 | Quarterly Result Announcement | NA | 0.73% |
| 2026-07-28 | 2026-07-28 | Quarterly Result Announcement | NA | 2.67% |
| 2026-07-28 | 2026-07-28 | Annual General Meeting | NA | -3.80% |
| 2026-07-17 | 2026-07-17 | Dividend | ₹ 75.00 /share | -3.64% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 4.09% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -0.19% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -4.06% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.68% |
| 2025-07-21 | 2025-07-21 | Annual General Meeting | NA | 20.59% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 35.00 /share | 32.64% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 30.00 /share | 32.64% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 3.80% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -5.60% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -6.42% |
| 2024-08-28 | 2024-08-28 | Annual General Meeting | NA | 0.34% |
Pfizer Competitors Screener - Peer Stocks Comparison
Screen PFIZER competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,036 | 40.80 | 61,674 | 12.69% | 11,565 | 60.77 |
| Divis Laboratories | 293,316 | 87.70 | 11,067 | 13.95% | 2,568 | 65.94 |
| Torrent Pharmaceuticals | 175,376 | 84.70 | 13,886 | 20.34% | 2,138 | 42.26 |
| Laurus Labs | 125,488 | 94.90 | 6,868 | 22.01% | 890 | 55.82 |
| Zydus Life Science | 119,900 | 27.90 | 27,658 | 17.64% | 5,026 | 55.22 |
| Dr Reddys Laboratories | 116,705 | 42.00 | 35,059 | 3.90% | 4,158 | 73.09 |
| Cipla | 114,474 | 39.20 | 29,045 | 2.24% | 3,870 | 62.07 |
| Mankind Pharma | 108,424 | 47.50 | 14,636 | 14.85% | 1,938 | 62.66 |
| Aurobindo Pharma | 103,355 | 25.90 | 34,145 | 5.56% | 3,503 | 60.69 |
| Lupin | 90,173 | 17.10 | 29,039 | 26.75% | 5,356 | 44.73 |
Pfizer Company Announcements - News & Reports Screener
Screen PFIZER latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 3, 2026.
The next most recent announcements are dated October 26, 2026 and October 9, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-03 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-26 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-29 | Closure of Trading Window | - |
| 2026-09-29 | Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-09-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-07 | Board Meeting Outcome for Discontinuation Of Minipress XL. | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-29 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-07-28 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-07-28 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-07-20 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2026. | - |
| 2026-07-17 | Response To Clarification Sought By BSE Limited. | - |
| 2026-07-17 | Clarification sought from Pfizer Ltd | - |
| 2026-07-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-07 | Letter To Shareholders Providing The Weblink To Access The Annual Report For Financial Year 2025-26. | - |
| 2026-07-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-06 | Shareholders Meeting - AGM Notice | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹3,850.30, within a 52-week range of ₹3,612.30 to ₹5,197.80. The P/E ratio is 20.30 and the P/B ratio is 3.98, with earnings per unit of ₹157.92. Market capitalisation stands at ₹17,575.36 Cr and the dividend yield is 1.97%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.